February 2, 2010

Clinical Trials: A Phase 1b Study to Evaluate the Safety and Tolerability of AMG 655 in Combination With Bortezomib or Vorinostat in Subjects With Relapsed or Refractory Lymphoma

Sponsor and Collaborators

Amgen

Contact

Continue Reading

Amgen Call Center

866-572-6436

Principal Investigator

MD Amgen

ClinicalTrials.gov Identifier

NCT00791011

Next post in Lymphoma Clinical Trials

Clinical Trials: A Phase II Study of Repeat Intranodal Injections of Adenovirus-CD154 (Ad-ISF35) in Patients With Non-Hodgkin’s Lymphoma (Follicular, Diffuse Large Cell, Mantle Cell and Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia)